LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health and artificial intelligence solutions for Latin America, announced today that its Venezuelan subsidiary, LATAMEDAI VE, has entered into an agreement with DROGUERIAS LALA C.A. to develop artificial intelligence-supported and automated software tools for pharmaceutical and laboratory operations.
The collaboration aims to design, develop, test, and evaluate customized technology intended to support workflows associated with pharmaceutical research, laboratory testing, quality-control processes, documentation, operational coordination, and data analysis. The proposed technology is expected to include software tools designed to organize and analyze information generated during pharmaceutical development and laboratory activities. Planned functionality may include workflow automation, testing coordination, document management, data review, quality-control support, and predictive analytical tools intended to help qualified personnel identify potential inconsistencies or operational issues at an earlier stage.
Under the agreement, LataMed AI and DROGUERIAS LALA C.A. will begin identifying specific workflows to be addressed, defining the platform’s technical and operational requirements, and establishing a phased development and testing process. The parties also intend to establish appropriate confidentiality, information-security, data-management, and access-control procedures.
The parties will evaluate whether the proposed technology can assist qualified personnel with the organization and review of information associated with pharmaceutical formulas, laboratory results, quality standards, testing procedures, and applicable approval processes. Any such functionality would be designed as a decision-support and workflow-management resource and would not independently approve pharmaceutical formulas, laboratory results, medical products, or regulatory submissions. Pharmaceutical, scientific, laboratory, or quality-control determinations would remain the responsibility of appropriately qualified professionals and applicable regulatory authorities.
“This agreement represents an opportunity to apply our artificial intelligence and automation capabilities within complex pharmaceutical and laboratory environments,” said Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp. “Our objective is to work with DROGUERIAS LALA C.A. to develop responsible technology that supports data analysis, documentation, testing coordination, quality-control processes, and other operational requirements while preserving appropriate professional oversight.”
Management believes the collaboration may provide an opportunity to expand LataMed AI’s technology into enterprise pharmaceutical and laboratory applications beyond its patient-facing telemedicine services. The initiative is consistent with the Company’s broader strategy of developing digital infrastructure and artificial intelligence-supported tools for healthcare providers, pharmacies, laboratories, institutions, and other participants in the healthcare ecosystem.
If successfully developed and implemented, management believes the resulting technology may provide a framework that could potentially be adapted for other pharmaceutical, laboratory, and healthcare organizations in Venezuela and elsewhere in Latin America. Any future expansion would remain subject to separate agreements, successful development and testing, operational readiness, applicable regulatory requirements, and the needs of participating organizations.
The parties will also evaluate the ownership, licensing, permitted use, and protection of any software, technology, data, or other intellectual property developed through the collaboration. The specific intellectual-property and commercialization terms will be governed by the agreement and any additional documentation entered into by the parties.
The agreement establishes the framework under which LataMed AI and DROGUERIAS LALA C.A. intend to develop and evaluate the proposed technology. It does not guarantee a specific implementation schedule, commercial deployment, reduction in operating costs or development timelines, scientific or regulatory outcomes, revenue, profitability, or expansion to additional organizations.
For additional information, please visit https://latamed.ai, follow the Company’s official social media channels, or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
